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A major neutralizing epitope (here referred to as the T332 epitope) located on the lateral surface of domain III (DIII) of the West Nile virus
(WNV) envelope protein has been identified based on the analysis of murine monoclonal antibodies. However, little is known about the humoral
immune response against WNV in a natural host or whether DIII in general or the T332 epitope in particular are important targets of neutralizing
antibodies in vivo. To characterize the types of antibodies produced during infection with WNV, we studied a group of naturally infected horses.
Using immune adsorption assays coupled with the use of virus particles bearing mutations in the T332 epitope, we found that in some animals
neutralizing activity against DIII and the T332 epitope was below the limit of detection. In contrast, some animals generated a significant fraction
of neutralizing activity to DIII and the T332 epitope. Thus, while antibodies to the T332 epitope did not represent a significant fraction of the total
antibody response in the infected animals studied, in some horses, they comprised a significant fraction of neutralizing activity, making this an
important but far from dominant neutralizing epitope. Rather, the neutralizing response to WNV generated in infected horses is both variable and
polyclonal in nature, with epitopes within and outside of DIII playing important roles.
© 2006 Elsevier Inc. All rights reserved.Keywords: West Nile virus; Neutralization; Flavivirus; Domain III; Envelope protein; HorsesIntroduction
West Nile virus (WNV), the causative agent of West Nile
fever and encephalitis, has rapidly spread throughout the
Western Hemisphere since its appearance in 1999. WNV is
not only an important human pathogen, but also a major
veterinary pathogen. Disease associated with WNV infection
has become a significant clinical and economic burden for the
equine industry in the United States, with 23,742 cases reported
throughout the country since 1999 (as of March 2006) (http://
www.aphis.usda.gov/vs/ceah/ncahs/nsu/surveillance/wnv/wnv.
htm). As in humans, the majority of WNV infections in horses
are subclinical, with a subset of horses developing neurologic
signs including paralysis, ataxia, muscle fasciculations and⁎ Corresponding author. Fax: +1 215 898 9557.
E-mail address: doms@mail.med.upenn.edu (R.W. Doms).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.08.047tremors. Among clinically affected horses, mortality rates range
from 30 to 40% (Murgue et al., 2001; Ostlund et al., 2001;
Porter et al., 2003; Salazar et al., 2004; Snook et al., 2001).
Although no specific anti-viral treatments for WNV exist to
date, several veterinary vaccines have been developed (Agrawal
and Petersen, 2003; Minke et al., 2004; Siger et al., 2004). In
addition, live, attenuated chimeric human vaccines are under-
going clinical trials (Arroyo et al., 2004; Monath et al., 2006;
Pletnev et al., 2006).
WNV virions contain two membrane proteins, pre-mem-
brane/membrane (prM/M) and envelope (E). The E protein
covers the majority of the viral surface and is the major target of
antibodies generated against WNV during infection. The hu-
moral immune response plays a critical role in protection from
and clearance of WNV infection in animal models (Ben-Nathan
et al., 2003; Camenga et al., 1974; Diamond et al., 2003a, 2003b;
Engle and Diamond, 2003; Gould et al., 2005; Tesh et al., 2002;
Fig. 1. Levels of WNV-specific IgG in naturally infected horses. WNV-specific
IgG antibodies present in horse serum samples were measured using WNV
subviral particles (SVPs) (A) or domain III (DIII) (B) as antigen. Horses 4–7
(black lines and symbols) represent uninfected controls. Horses 9–20 (gray lines
and symbols) represent WNV-infected horses. Normalized optical density (OD)
values are shown. Two WNV-infected horses had undetectable levels of WNV-
specific IgG in this assay (9 and 12). Results represent the average of two
independent experiments.
337M.D. Sánchez et al. / Virology 359 (2007) 336–348Wang et al., 2001). The protective effects of WNV-specific
antibodies may be attributed to several different functional
properties including an ability to fix complement, mediate
antibody-dependent cytotoxicity and to directly interfere with
the attachment or entry of virions. The latter process has been
studied extensively in vitro (Beasley and Barrett, 2002; Gollins
and Porterfield, 1986; Gould et al., 2005; Oliphant et al., 2005;
Peiris et al., 1982; Sanchez et al., 2005).
Flavivirus E proteins fold into three structural domains: I, II
and III (Modis et al., 2003, 2005; Rey et al., 1995). The large
majority of the potent murine neutralizing monoclonal anti-
bodies (MAbs) described to date against WNV bind to domain
III (DIII), specifically to an epitope on the lateral surface of DIII
described in the literature as a dominant neutralizing epitope
(Beasley and Barrett, 2002; Oliphant et al., 2005; Sanchez et al.,
2005). This neutralizing epitope includes residues clustered
around amino acids 306, 307, 330, and 332 and is referred to
here as the T332 epitope. An additional neutralizing epitope in
DIII has been described involving residues 310 and 394, where
a weakly neutralizing MAb mapped (Oliphant et al., 2005).
Many neutralizing antibodies against related flaviviruses bind to
DIII, although neutralizing antibodies against other domains
have also been described (Mandl et al., 1989; Roehrig, 2003;
Roehrig et al., 1998).
While the most potent neutralizing MAbs to WNV described
to date bind to DIII, and in particular to the T332 epitope, these
antibodies have been derived by experimental vaccination and
infection of rodent animal models. The importance of DIII
neutralizing epitopes during natural WNV infection remains to
be determined. In this study, we investigated the importance and
prevalence of antibodies against DIII, including the T332
epitope, during natural WNV infection in horses. We found that
horses make antibodies to epitopes throughout the E protein,
including the T332 epitope. However, removal of DIII-specific
antibodies reduced the neutralizing activity of serum from only
a subset of horses. Likewise, WNV particles bearing multiple
mutations in the T332 epitope were effectively neutralized by
all horse sera examined, though sometimes less efficiently.
Therefore, DIII is an important target for neutralizing antibodies
in some but not all infected animals. Furthermore, the T332
epitope, while sometimes important, is not a predominant
neutralizing determinant in WNV-infected horses. Rather, the
neutralizing antibody response in infected horses is clearly
polyclonal in nature, with epitopes within and outside of DIII
being targeted.
Results
Antibody response against WNV in naturally infected horses
A group of WNV-infected horses was studied to examine the
types of antibodies produced during natural infection and to
determine if epitopes in domain III (DIII) of the envelope (E)
protein are important for neutralization of WNV in vivo. WNV-
infected horses used in this study were examined at the School
of Veterinary Medicine at the University of Pennsylvania during
2003. Serum from control uninfected horses was collected at theSchool of Veterinary Medicine at the University of Pennsylva-
nia prior to the introduction of WNV into the Western
Hemisphere. Serum samples from uninfected (control) and
WNV-infected horses were examined for antibody levels (IgG
and IgM) and neutralization titers. IgG levels were measured by
assessing the reactivity of horse serum to WNV subviral
particles (SVPs) and purified WNV DIII protein by ELISA
(Sanchez et al., 2005). SVPs are non-infectious virus-like
particles lacking the capsid protein and genomic RNA that are
secreted from cells expressing full-length prM and E proteins
and share many of the antigenic and functional properties of
native mature virus particles (Allison et al., 1995; Hanna et al.,
2005; Hunt et al., 2001; Konishi and Fujii, 2002; Konishi et al.,
1992, 2001; Kroeger and McMinn, 2002; Mason et al., 1991;
Schalich et al., 1996). SVPs were used to determine the overall
immune response against the envelope proteins of WNV (prM/
M and E) while the purified DIII protein was used to assess
specific responses against the domain incorporating the
conserved T332 epitope (Beasley et al., 2004; Beasley and
Barrett, 2002; Oliphant et al., 2005; Sanchez et al., 2005).
Sera from infected horses exhibited considerable variability
in their reactivity to both SVPs and DIII, both with regard to
antibody titer (IgG) as well as maximal reactivity seen at
338 M.D. Sánchez et al. / Virology 359 (2007) 336–348saturating concentrations of antibody (Fig. 1). All uninfected
(control) horses and two WNV-infected horses (Horses 9 and
12) had little to no antibody reactivity to SVPs or to DIII. WNV-
specific IgM antibodies were detected in the serum of horse 9
which suggests that the sample was obtained during the acute
period of infection before the animal was able to mount a robust
IgG response (data not shown). Horse 12, a 9-month-old foal,
did not have any detectable IgM in its serum, which suggests
that this young animal was unable to mount an immune
response to viral infection. Despite variability in antibody levels
(IgG), sera from all animals exhibited similar reactivity to both
SVPs (Fig. 1A) and purified DIII (Fig. 1B).
We also tested the reactivity of horse sera against a panel of 56
overlapping peptides (15–19 amino acids in length) spanning
the entire length of the E protein (Peptide Array West Nile Virus
Gene E, NIH Biodefense and Emerging Infections Research
Resources Repository, NIAID) to identify linear epitopes recog-
nized during the course of infection. However, the majority of
the naturally infected horses did not produce IgG antibodies that
reacted with any of the linear epitopes encoded by this peptide
library, while a few horses reacted with two peptides spanning
sequences on domain II that, based on the structure of the dengue
virus E protein, are likely to be surface exposed (Table 1). No
single peptide was recognized by all horses, and most horses
showed very weak reactivity to the positive peptides. Therefore,
naturally infected horses do not efficiently produce antibodies
against short, linear epitopes of the E protein.
Domain III epitopes targeted during natural infection
To determine the contribution of antibodies that bind residues
on DIII to the total humoral immune response in horses during
WNV infection, we performed experiments to determine if the
binding of horse serum to soluble DIII could block subsequent
binding of monoclonal antibodies (MAbs) to this protein. The
majority of the potent murine neutralizing antibodies described
against WNV map to the T332 epitope, which is on the lateral
surface of DIII (Beasley and Barrett, 2002; Oliphant et al., 2005;
Sanchez et al., 2005). Although many antibodies are produced
against other regions of the E protein in mice, the region
surrounding the T332 epitope seems to be a preferred target for
the production of potent neutralizing antibodies. Three MAbs
were used in these experiments: 4E1, 8B10 and 11C2 (Sanchez
et al., 2005).MAbs 8B10 and 11C2map to the T332 neutralizing
epitope onDIII (Fig. 4A), while 4E1maps outside of this epitope
at an undetermined location in DIII. ELISA plates were coatedTable 1
Reactivity of WNV positive horse serum against linear epitopes
Peptide Sequence
10 63LSTKAACPTMGEAHNDKR80
11 71TMGEAHNDKRADPAFVCR88
Peptides tested span the entire length of the WNV E protein. The number of the pep
determined for each horse using an average of the absorbance values of the lower 10 p
and divided into three groups: 4- to 6-fold, 6- to 8-fold and >8-fold. The total numb
absorbance of more than 4-fold the cut-off value are listed. A few peptides were consis
positive horses, therefore reactivity with these peptides was deemed to be non-specwith a purified WNV DIII protein after which serial dilutions of
horse sera were added to the wells and allowed to bind for 1 h.
The time of incubation and amount of horse serum added were
optimized to ensure maximal occupation of antibody binding
sites on DIII. Non-saturating concentrations of the indicated
MAbs were subsequently added for 20 min, the least amount of
time needed to achieve adequateMAb binding. This was done to
minimize the possibility of the MAbs competing off lower
affinity equine antibodies. A decrease in the amount of MAb
binding to DIII would suggest that, under the conditions tested,
the specific horse serum has antibodies targeting the same region
where the MAb binds.
Competition ELISAs were performed with horses that had
intermediate (horses 10, 17 and 18) or high titers (horses 11, 14,
15, 16 and 19) of anti-WNV antibodies (IgG) as measured by
ELISA (see Fig. 1). Horses with high WNV ELISA titers
efficiently blocked binding of neutralizing MAbs to DIII, most
at serum dilutions ranging from 40-fold to 80-fold (Fig. 2A,
MAb 8B10). Decreasing amounts of serum decreased the ability
to block MAb binding as expected (40-fold vs. 160-fold
dilution). These results indicated that the T332 neutralizing
epitope is a target of the humoral immune response during
natural infection of WNV in horses. Other sites on DIII are also
targets since sera from these horses were able to block infection
of a different MAb (4E1) which binds outside of this dominant
neutralizing epitope (Fig. 2B). However, sera from horses with
intermediate titers by ELISA (10, 17 and 18) did not block or
weakly blocked subsequent binding of both MAbs. This
suggests that these horses either do not have significant levels
of antibodies against regions in DIII or that horses could have
low affinity antibodies that were unable to compete with high
affinity MAbs, and therefore not detected by the competition
assay. Lower affinity antibodies may also explain the lower IgG
titers obtained (Fig. 1) in those serum samples. No correlation
was evident between the antibody blocking ability of serum
samples and levels of WNV-specific IgM (data not shown).
Since the purified DIII fragment lacks other domains of the E
protein that may be targeted during the immune response, we
repeated the competition ELISAs with a subset of horse serum
samples using SVPs rather than soluble DIII as the antigen. We
performed experiments to determine if the binding of horse
serum to SVPs could block subsequent binding ofMAbs to the E
protein in the context of a polyvalent virus particle. When SVPs
were used as antigen, similar patterns of competition were
observed with all DIII antibodies (4E1, 8B10 and 11C2) and a DI
antibody (17D7) (Fig. 3). Interestingly, the degree to which4 to 6-fold 6 to 8-fold >8-fold
0 1 (H 11) 1 (H 16)
1 (H 17) 0 2 (H 16, 18)
tide, the sequence and magnitude of reactivity are shown. Cut-off values were
eptides. Absorbance values of more than 4-fold the cut-off values were calculated
er of horses and the specific horse (H) which reacted with the peptides with an
tently positive (to the same level) with control, uninfected horses and with WNV
ific.
Fig. 2. Serum from WNV-infected horses blocks subsequent binding of mono-
clonal antibodies (MAbs) to WNV DIII. Purified DIII proteins were incubated
with different dilutions of horse serum fromWNV positive horses (10, 11, 14–19)
or an uninfected control horse (C; used at 1:20 dilution). Dilutions of horse serum
were performed at a range of 1:20–1:640 (2–64 on x-axis). Each horse is shown
with the highest dilution first (i.e. 16, or 1:160) followed by lower dilutions and,
therefore, increasing amounts of horse serum. Subsequent to horse serum binding,
incubation with MAbs against DIII (8B10, 4E1) was performed. Binding of
MAbs was detected with an anti-mouse HRP conjugate. Percentage binding of the
MAb represents the percent of signal obtained with incubation with serum from
the uninfected control horse. Error bars represent the standard error of the mean.
Increasing concentrations of most horse seras tested decreased subsequent
binding of the MAbs tested to DIII.
Fig. 3. Serum from WNV-infected horses blocks subsequent binding of
monoclonal antibodies (MAbs) to subviral particles (SVP). SVPs were incubated
with different dilutions of horse serum from a subset ofWNVpositive horses (10,
15, 19) or an uninfected control horse (C; used at 1:80 dilution). Dilutions of
horse serum were performed at a range of 1:80–1:4920 (8–492 on x-axis). Each
horse is shown with the highest dilution first (i.e. 128 or 1:1280) followed by
lower dilutions and, therefore, increasing amounts of horse serum. Subsequent to
horse serum binding, incubation with MAbs against DIII (11C2, 8B10, 4E1) or
DI (17D7) was performed. Binding of MAbs was detected with an anti-mouse
HRP conjugate. Percentage binding of the MAb represents the percent of signal
obtained with incubation with serum from the uninfected control horse. Error
bars represent the standard error of the mean. Increasing concentrations of the
horse seras tested decreased subsequent binding of all MAbs to SVPs.
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greater when SVPs were used as the antigen. In addition, horse
sera that did not block binding of MAbs to DIII (see Horse #10)
did block binding of MAbs to SVPs, although the degree of
blocking was less than with other horse sera. These differences
could be due to a higher avidity of antibodies in horse sera
against the E protein in the context of a virus particle.
Alternatively, since E proteins exist as dimers on the surface
of virus particles (Kuhn et al., 2002; Mukhopadhyay et al.,
2003), binding of an antibody to one E protein could block
subsequent binding of an antibody to a different site on an
adjacent E protein. Nonetheless, these experiments show that
horses naturally infected with WNV produce antibodies against
several regions in DI and DIII, including antibodies that can
block subsequent binding of MAbs to the T332 neutralizing
epitope.After establishing that horses infected with WNV produce
antibodies to DIII, we sought to determine if the majority of
antibodies produced against DIII were against the T332
neutralizing epitope. To do this, we determined if sera from
WNV-infected horses could detect a purified DIII protein where
340 M.D. Sánchez et al. / Virology 359 (2007) 336–348four critical residues in the conserved neutralizing epitope were
mutated (306, 307, 330 and 332; Δ67IA) (Fig. 4A). Wild-type
(WT) and mutant Δ67IA DIII proteins were used in ELISA toFig. 4. Mutations in DIII of the WNV Envelope protein. (A) Diagram of the
WNV Envelope protein with an enlarged schematic of domain III (in blue) with
residues mutated for either reporter virus particle (RVP) or purified DIII
production. In red are residues 306, 307, 330 and 332 (Δ67IA mutant) and in
green are residues 310 and 394. (B) Neutralization assays with wild-type and
mutant (Δ67IA and Δ310/394) RVP luciferase and monoclonal antibodies
(MAbs). RVPs were incubated with no antibody (0, No Ab) or with two
concentrations of MAbs (10 μg/ml or 0.1 μg/ml). Infections were normalized to
the amount of luciferase produced when RVPs were not incubated with antibody
(No Ab). MAb 17D7 maps to DI and is non-neutralizing. Neutralizing MAbs
11C2 and 8B10 map to residues 306/307/330/332 which have been mutated in
Δ67IA RVPs, therefore these MAbs lose neutralizing activity with this mutant.
Neutralizing MAb E1 maps to residues 310/394 which have been mutated in
Δ310/394 RVPs, therefore E1 lost neutralizing activity with this mutant. Error
bars represent the standard error of the mean.determine reactivity of sera from control and WNV-infected
horses. All horse sera with titers high enough to reliably detect
the WT DIII protein also readily detected the mutant Δ67IA
DIII protein (data not shown), indicating that antibodies
dependent upon residues 306, 307, 330 and 332 comprise
only a minor fraction of all the antibodies directed against DIII.
Reporter virus particle neutralization assay
To determine the functional properties of antibodies present
in the sera of each horse, we utilized a recently described
reporter virus particle (RVP)-based neutralization assay to
characterize the neutralizing activity in each serum sample
(Pierson et al., 2006). The RVP neutralization assay employs
particles that are capable of only one round of infection and
encapsidate a sub-genomic RNA that expresses a reporter
protein. We have recently completed a study examining the
equine neutralizing antibody response using both the RVP-
based neutralization assay and traditional assays that utilize
infectious virus to confirm that this novel assay reliably detects
neutralization activity in serum samples from infected animals
(unpublished data). All WNV-infected horses exhibited neu-
tralizing activity except horse 12, which did not have detectable
WNV-specific IgM or IgG antibodies by ELISA (Fig. 1 and data
not shown). One of the uninfected control horses (#4) had very
weak neutralizing activity against RVPs (Table 2). It is possible
that this horse was infected with a related flavivirus (i.e. Saint
Louis encephalitis virus) and had developed cross-reactive
antibodies against WNV. For this group of naturally infected
horses, the levels of IgG antibodies (Fig. 1) did not correlate
with the strength of the neutralization titers (Table 2), which
may imply that low antibody titers do not necessarily translate
into weak neutralizing activity or lack of protection from
disease (Davis et al., 2001; Siger et al., 2004; Tesh et al., 2002).
It is possible that making antibodies against a few specific
residues may provide a sufficient amount of protection against
the virus if these antibodies target key residues in the protein.
Neutralization of mutant reporter virus particles
Our MAb competition studies indicated that WNV-infected
horses produce antibodies that bind to or near the T332 neutra-
lization epitope in DIII. To determine if antibodies to this epitope
comprise a significant fraction of neutralizing antibodies in vivo,
we produced RVPs bearing mutations in DIII that prevent
binding of antibodies to two major neutralizing epitopes. We
prepared RVPs in which residues 306, 307, 330 and 332
(Δ67IA) were mutated, or in which residues 310 and 394 (Δ310/
394) were mutated (Fig. 4A). Neutralization assays were then
performed using WT and mutant RVPs to ensure that the muta-
tions abrogated binding of MAbs targeting the mutated epitopes
(Fig. 4B). Four different MAbs were used: 17D7 binds to do-
main I and is not neutralizing: 8B10 and 11C2 are neutralizing
MAbs that map to the epitope comprised of residues 306, 307,
330 and 332; and E1 maps to the neutralization epitope com-
prised of residues 310 and 394 (Oliphant et al., 2005; Sanchez et
al., 2005). All neutralizing MAbs (8B10, 11C2 and E1)
Fig. 5. Mutations in residues 306/307/330/332 (Δ67IA) can affect neutralizing
activity of horse serum. Scatter plot shows results from at least 12 independent
neutralization assays with reporter virus particles expressing luciferase as a
reporter protein. The EC50 neutralization titers were calculated using non-linear
regression curve fits. The ratio of the EC50 neutralization titer for wild-type
(WT) over mutant (Δ67IA) is plotted (WT/67IA). Each symbol represents the
ratio of an independent experiment. Horizontal bars represent the mean of the
ratios. A ratio of 1 indicates that there was no difference in neutralization of
WT or mutant reporter virus particles. The larger the ratio (>1), the more horse
serum was required to neutralize the mutant versus the WT. Table shows results
of statistical analysis of the difference in EC50 titer between WT and Δ67IA
(two-tail paired t-test). P value<0.05 is significant. Mean EC50 ratios
(WTEC50/Δ67IAEC50) and confidence intervals for the ratios obtained are
shown.
Table 2
Average neutralization titers of WNV-infected horses
Horse no. Average EC50 titer (reciprocal dilution)
4 (C) a 272.4
5 (C) <40
6 (C) <40
7 (C) <40
9 187,875
10 4033
11 34,794
12 <40
14 26,153
15 40,689
16 42,031
17 108,178
18 104,300
19 139,979
20 20,534
The reciprocal of the dilution of horse serum required to block 50% of infection
(EC50) on Vero cells is shown. At least two independent replicates were
averaged for each horse serum sample.
a C—control, uninfected horses.
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weakest activity as previously described (Oliphant et al., 2005).
When the Δ67IA mutant RVPs were tested, the MAbs which
map to the residues mutated (8B10 and 11C2) were not able to
neutralize infection, while neutralization of these particles by E1
was not affected. In contrast, when residues 310/394 were
mutated, E1 lost neutralizing activity, while 8B10 and 11C2
effectively neutralized this mutant particle. These results suggest
that the mutations engineered into the envelope protein do not
significantly affect the overall structure or arrangement of the E
protein on the virus particle since the resulting virus particles
were infectious and retained the ability to bind antibodies that
react with distant epitopes.
To address the prevalence of antibodies against the T332
neutralizing epitope in horses naturally infected with WNV, we
performed neutralization assays utilizing the mutant RVPs. We
hypothesized that if the majority of neutralizing activity present
in horse serum is against these neutralization epitopes (306/307/
330/332 or 310/394), these horses would have decreased ability
to neutralize the mutant RVPs. In contrast, if the majority of
neutralizing activity elicited by natural WNV infection targets
other regions of the E protein, then the mutant RVPs should be
neutralized as efficiently as wild-type (WT) RVPs. It is
important to note that, in our assays, the concentration of
antigen present in RVP preparations was sufficiently low to
allow measurements of neutralization at steady state and
achieve results that are independent of the concentration of
RVPs used (Pierson et al., 2006). WT and mutant RVPs were
incubated with dilutions of horse serum and 50% neutralization
titers (EC50) calculated. EC50 titers were similar for all horses
tested with WT and Δ310/394 mutant particles (data not
shown), suggesting that antibodies directed to the epitope
defined by residues 310/394 do not comprise a significant
fraction of the neutralizing activity in serum from WNV-
infected horses. However, when the Δ67IA mutant RVPs were
used, different results were obtained. Sera from some infectedhorses neutralized Δ67IA RVPs as effectively as WT particles.
However, for a subset of the horses, significantly higher
concentrations of serum were required to neutralize the mutant
Δ67IA particles than WT. For these horses (horses 11, 16 and
19), the EC50 neutralization titers differed 2- to 5-fold between
the mutant Δ67IA and WT particles (Fig. 5A and B). Thus, in
some but not all WNV-infected animals, antibodies that bind to
the DIII epitope that includes residues 306, 307, 330 and 332
comprise a significant fraction of total neutralizing activity.
Levels of WNV-specific IgM did not correlate with the
neutralization potency of serum samples against wild-type
versus mutant reporter virus particles (data not shown).
Impact of DIII neutralizing antibodies
Our data showed that, while some WNV-infected horses
produce significant neutralizing activity against the T332
neutralization epitope in DIII, others do not. To determine if
in these animals neutralizing antibodies might bind to other as
yet unidentified epitopes in DIII, we performed serum depletion
studies. To do this, horse serum was incubated with beads
coated with purified DIII protein, after which the beads were
removed. In addition, horse serum was incubated with beads
without DIII to control for non-specific removal of antibodies
342 M.D. Sánchez et al. / Virology 359 (2007) 336–348by beads. We confirmed that this procedure effectively removed
DIII antibodies from the sera as assessed by ELISA (Fig. 6A).
Neutralization assays were then performed. If a large fraction of
the neutralizing antibodies in horse serum are against DIII, we
would expect to see a decrease in neutralizing activity after
removal of DIII-specific antibodies. We found that removal of
DIII antibodies from sera obtained from horses 10 and 15 hadFig. 6. Removal of DIII-specific antibodies affects neutralization activity in a subset
antibodies by ELISA before binding to beads (pre-beads, white bars) or after binding b
bars). A control, uninfected horse serum is shown for background (C). For all WNV p
antibodies, while incubation with beads without DIII did not non-specifically remo
density. (B) Neutralization assays with serum pre-beads or after treatment with beads fr
treated with ‘No DIII’ beads (▲, triangles) or serum treated with ‘DIII’ beads (●, cir
expressing GFP measured by flow cytometry 44 h after infection. For some horses (se
the serum. However, for other horses (see 11, 16 and 19), removal of DIII antibodies de
infection. One representative graph from each horse is shown.no effect on neutralization titers, suggesting that in these horses
most neutralizing antibodies are directed against epitopes
outside of DIII or to epitopes that are not present in soluble,
monomeric DIII. These results are consistent with the fact that
sera from horses 10 and 15 neutralized the Δ67IA DIII mutant
as effectively as wild-type virus particles. In contrast, removing
DIII antibodies from sera obtained from horses 11, 16 and 19of horses. (A) Horse serum samples were tested for the presence of DIII-specific
eads with or without DIII protein (Beads-No DIII, black bars or Beads-DIII, gray
ositive horses, incubation with DIII beads removed the majority of DIII specific
ve DIII antibodies. Error bars represent the standard deviation. O.D.—Optical
om part A. RVPswere incubated for 1 hwith serum pre-beads (■, squares), serum
cles). Vero cells were infected after the incubation time and the percent of cells
e 10 and 15), removal of DIII antibodies did not affect the neutralizing activity of
creased the neutralizing activity of the serum. The control horse did not neutralize
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6B). For horses 16 and 19, the effect of removing DIII-specific
antibodies was more prominent than for horse 11. This suggests
that a significant fraction of neutralizing activity in these horses
is produced against DIII since removal of these antibodies
noticeably decreased the neutralizing activity of the serum. This
conclusion is also supported by the fact that sera from these
animals neutralized the Δ67IA DIII mutant at least several fold
less effectively than wild-type virus. Combined, these data
indicate that, in some naturally infected horses, a significant
fraction of the neutralizing activity targets not only DIII, but the
T332 neutralizing epitope on the lateral surface of DIII. Indeed,
removal of DIII antibodies from serum of these three horses had
an almost identical effect on neutralizing activity as the use of
the Δ67IA DIII mutant RVPs, which confirmed that in this
subset of horses other epitopes in DIII were not targeted by
neutralizing antibodies (data not shown). However, other
infected animals mounted highly effective neutralizing
responses that most likely involve determinants outside of DIII.
Discussion
Previous studies have shown the importance of an intact
humoral immune response in controllingWest Nile virus (WNV)
infection in animal models (Ben-Nathan et al., 2003; Camenga et
al., 1974; Diamond et al., 2003a, 2003b; Engle and Diamond,
2003; Gould et al., 2005; Halevy et al., 1994; Tesh et al., 2002;
Wang et al., 2001). Case reports of recovery after treatment with
WNV-specific immunoglobulin preparations in human patients
(Agrawal and Petersen, 2003; Haley et al., 2003; Hamdan et al.,
2002; Shimoni et al., 2001) have provided additional incentives
to understand the humoral immune response generated during
infection and to create treatments based on antibodies. In
addition, recent studies with monoclonal antibodies have
provided insight about neutralization epitopes on the WNV
envelope (E) protein and mechanisms of viral neutralization by
antibodies (Beasley and Barrett, 2002; Gould et al., 2005;
Oliphant et al., 2005; Sanchez et al., 2005). However, little is
known about the humoral immune response in a natural host of
infection. In this study, we investigated the antibody response
against WNV during natural infection of horses to improve our
understanding of the epitopes targeted during infection in a
natural host for the virus.
The majority of the potent neutralizing murine MAbs that
have been described to date bind to DIII of the WNV E protein
(Beasley and Barrett, 2002; Oliphant et al., 2005; Sanchez et al.,
2005), with many of these binding to the T332 epitope on the
lateral surface of DIII. Studies with murine MAbs have also
shown that a group of neutralizing MAbs againstWNValso map
outside of DIII, although these tend to be less potent than
antibodies against DIII (Oliphant et al., 2005; Razumov et al.,
2005). Humans infected with WNV produce antibodies that can
block binding of MAbs to the T332 epitope, but whether this
region is an important neutralization target in vivo is not known
(Oliphant et al., 2005). Human phage display libraries have been
used to identify neutralizing single-chain variable region
antibody fragments that bind to epitopes in DI and/or DII(Gould et al., 2005). Similarly, primate or human-derived
antibodies isolated from Fab libraries for other related
flaviviruses have mapped outside of DIII (Daffis et al., 2005;
Goncalvez et al., 2004b). Therefore, the WNV E protein
presents a variety of neutralizing epitopes of uncertain in vivo
significance.
We sought to determine if epitopes in DIII, and the so called
dominant neutralizing T332 epitope in particular, are important
targets for neutralizing antibodies during natural WNV infection
in a group of horses. Horses serve as a good model to study
WNV infection in a natural host. As in humans, the majority of
infections in horses are subclinical, with a subset of horses
developing devastating neurologic disease. In addition, both
horses and humans develop low levels of viremia after infection
and are considered dead-end hosts for WNV transmission.
Previous serologic surveys have shown that naturally infected
horses develop strong neutralizing antibody responses against
the virus (Davidson et al., 2005; Schmidt and Elmansoury,
1963). However, it is not known which epitopes are targeted by
the antibodies generated after natural infection of equines in the
field.
The majority of WNV-infected horses developed a robust
humoral immune response (IgG) against SVPs and a purified
DIII protein. Interestingly, the infected horses preferentially
produced conformational antibodies against the E protein since
the serum samples showed poor reactivity against a library of
overlapping peptides spanning the entire length of the WNV E
protein. An earlier study has shown that immunization with
denatured E protein fragments failed to induce neutralizing
antibodies in rabbits (Wengler, 1989), though studies with
dengue virus have shown that humans infected with the virus
produce antibodies against a variety of linear epitopes on the E
protein (Aaskov et al., 1989; Innis et al., 1989). It is unclear if the
difference in our results is due to the differences between
flaviviruses or a species difference.
We found that sera from WNV-infected horses readily
recognized both a purified wild-type DIII protein and a DIII
protein with four mutations in the T332 neutralizing epitope
(data not shown). Thus, antibodies that bind to the T332 epitope
were not prevalent in the sera of the naturally infected horses
studied here. However, a more important question is whether
DIII and the T332 epitope are significant targets for neutralizing
antibodies. Using two independent approaches, we found that
horses showed variability on the epitopes targeted by the
neutralizing antibody response. Sera from some infected animals
neutralized WNV particles bearing multiple mutations in the
T332 epitope as efficiently as wild-type particles. Likewise,
when antibodies to soluble DIII were removed from these sera,
neutralization titers were not affected. Thus, for some animals,
neutralizing activity against both DIII and the T332 epitope were
below the detection limit of our high-throughput neutralization
assay. In contrast, some infected animals did appear to generate a
significant fraction of neutralizing activity to DIII. When DIII
antibodies were adsorbed from these sera, neutralizing titers
were consistently reduced several fold. Likewise, while sera
from these animals could neutralize particles bearing multiple
mutations in the T332 epitope, titers were again reduced several
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generated against DIII, the T332 neutralizing epitope on the
lateral surface of DIII is a functionally important major target. In
addition, while T332 specific antibodies may not represent a
significant fraction of the total antibody response after infection,
in a subset of horses, they do comprise a significant fraction of
neutralization activity.
Our data indicate that, in horses naturally infected withWNV,
neutralizing activity directed against the T332 epitope, and more
generally DIII, is not consistently detected even though the T332
epitope is conserved among many WNV strains (Li et al., 2005;
Nybakken et al., 2005). Given recent reports of neutralizing
monoclonal antibodies outside of DIII (Goncalvez et al., 2004a,
2004b; Gould et al., 2005; Oliphant et al., 2005; Razumov et al.,
2005), we speculate that DII may be an important target for
neutralizing antibodies in these horses. While the neutralization
epitopes in DIII may be important and definitely favored in the
isolation of potent neutralizing MAbs derived from mice, they
are clearly not the only neutralizing epitopes targeted during
natural infection. It is evident that neutralizing antibodies against
other regions of the envelope protein can be effective in
neutralizing virus infection in vitro and are produced in vivo.
Materials and methods
Cell lines
Human embryonic kidney cells (HEK) 293Twere maintained
in Dulbecco's Modified Essential Media (DMEM) (Life
Technologies, Gaithersburg, MD) containing 10% fetal calf
serum (FCS) and 1% penicillin/streptomycin (P/S) (Invitrogen,
Carlsbad, CA). Vero cells weremaintained inMinimumEssential
Media (MEM) supplemented with 10% FCS/1% P/S/1% L-glu-
tamine. All cell lines were maintained at 37 °C in 5% CO2.
Horse serum samples
Samples were obtained from WNV-infected horses seen at
the School of Veterinary Medicine at the University of
Pennsylvania-New Bolton Center during 2003. All blood
samples were obtained during either acute infection or post-
mortem analysis of patients. Horses were diagnosed with WNV
infection by virus detection (virus isolation, RT-PCR, immu-
nohistochemistry) or WNV-specific antibody detection as
detailed by the Center for Disease Control and Prevention
guidelines (http://www.cdc.gov/ncidod/dvbid/westnile/resources/
wnv-guidelines-apr-2001.pdf). Detailed clinical information re-
garding outcome of infection or time of blood sample relative to
infection was not available for most horses. Control, uninfected
serum samples were collected from control horses housed at New
Bolton Center in 1992, prior to the introduction of WNV into the
Western Hemisphere.
Production of subviral particles
Wild-type SVPs were produced by lipid-mediated transfec-
tion of HEK 293T cells with a DNA plasmid encoding wild-type Lineage I pre-membrane/membrane and envelope protein
(prM-E) from strain NY99-6480 (pCBWN) (Davis et al.,
2001) following manufacturer's instructions (Lipofectamine
2000, Invitrogen). Five to six hours after transfection, the
media was changed to a low-glucose formulation of DMEM.
Supernatants were harvested 48 h after transfection, clarified
by low-speed centrifugation, filtered through a 0.45 μm-pore
size filter, and ultracentrifuged in Beckman SW41Ti rotor at
4 °C as previously described (Sanchez et al., 2005). For
unpelleted SVPs, supernatants were harvested, filtered and
stored at 4 °C.
WNV DIII protein production
Production and purification of the WNV DIII protein
(WED3) in bacteria have been previously described (Sanchez
et al., 2005). Briefly, a fragment containing amino acid residues
296–415 was amplified by PCR and cloned into the pBAD/Thio
TOPO expression vector (Invitrogen). TOP10 Escherichia coli
cells were transformed and 5-liter cultures grown and induced
with arabinose, as specified by the manufacturer. The protein
was purified under denaturing conditions, dialyzed against PBS,
quantified and purity assessed by silver stain. Proper folding of
the DIII fragment was assessed by reactivity with conforma-
tional MAbs by ELISA.
The following amino acid residues in domain III were
mutated using the QuikChange Site-Directed Mutagenesis kit
(Stratagene): S306A, K307R, K310A, T330I, T332A and
N394A. Double and quadruple mutants of these residues
were produced as follows: Δ310/394 and Δ306/307/330/332.
Sequence analysis of the entire open-reading frame confirmed
that the only mutations present were those listed above.
ELISAs
Horse serum titers were evaluated by ELISA using both
purified DIII protein and pelleted wild-type SVPs as antigen. For
experiments using DIII as antigen, 0.5 μg/ml of DIII was ad-
sorbed on 96-well plates (Immulon 2 HB, Thermo Labsystems)
in ELISA coating buffer (0.15 M sodium carbonate, 0.35 M
sodium bicarbonate in PBS pH 9.6) overnight at 4 °C. Plates
were washed using an automatic plate washer (Ultrawash PLUS
Microplate Washer, Dynex Technologies) with PBS/0.05%
Tween 20 and blocked with PBS/0.05% Tween/1% BSA for 1
h at room temperature (RT). Two-fold serial dilutions of horse
serum were added to the plate and allowed to bind for 1 h. After
washing, a rabbit anti-horse IgG antibody (Sigma) was added at
a 1:5000 dilution and allowed to incubate for 1 h. Following a
final wash, TMB Peroxidase Substrate and Peroxidase Substrate
solution B (KPL) were mixed at 1:1 dilution, 100 μl added to
each well, the reaction stopped with 50 μl 2MH2SO4 per well
and optical density at 450 nm (OD450) measured. For experi-
ments using SVPs as antigen, 100 ng/well of the E-specific
flavivirus MAb 4G2 was coated on plates in coating buffer
overnight. After washing, a 1:60 dilution of pelleted SVPs was
added to the plates and allowed to bind for 2 h. The rest of the
ELISA was performed as described above. OD values for all
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11 serum at the highest dilution (1:40) to 100%. Horse 11 was
chosen as a normalization control due to its high titer of
antibodies to the WNV E protein. Serial dilutions of horse 11
sera were included on all plates to control for variability between
plates and between experiments performed on different days.
Therefore, values are presented as a percent of the maximal
value of horse 11 (normalized O.D. values).
Peptide library ELISAs were performed as follows. Peptides
were obtained from the NIH Biodefense and Emerging Infec-
tions Research Resources Repository, NIAID, NIH (Peptide
ArrayWest Nile Virus Gene E). The 67-peptide array spans the E
gene of the NY99-flamingo382–99 strain of West Nile Virus
(GenbankAF196835). Peptides are 15- to 19-mers, with 10 or 11
amino acid overlaps. ELISA plates were coated with 3 μg of
each peptide overnight in ELISA coating buffer. After overnight
incubation, the plates were washed and blocked with PBS/
0.05% Tween/10% FCS for 1 h at RT. Horse serum was added to
the plates at a 1:100 dilution and incubated for 2 h at RT. After
washing, anti-horse IgG antibody (Sigma) was added at a 1:5000
dilution and allowed to incubate for 1 h. Development of plates
was performed as described above. The cut-off value for the
determination of positive peptides was established by averaging
the absorbance levels of the 10 lowest signal peptides for each
horse. Any peptide with an absorbance level higher than 4-fold
the cut-off value for each horse was determined to be positive.
Peptides that were positive with control, uninfected horses were
not counted as positive even if they also reacted with the WNV
positive horses.
Competition binding ELISAs
Competition ELISAs were performed using both purified
DIII protein and wild-type SVPs as antigen. For DIII
competition ELISAs, 0.5 μg/ml of WNV DIII protein was
adsorbed in ELISA coating buffer overnight at 4 °C. Plates were
washed with PBS/0.05% Tween 20 and blocked with PBS/
0.05% Tween/1% BSA for 1 h at RT. Horse serum samples from
WNV naturally infected horses were diluted from 1:20 to 1:640
in PBS/0.05% Tween/1% BSA and incubated at RT for 1 h.
These horse serum dilutions corresponded to the concentration
sufficient to saturate the DIII binding sites. After incubation with
the horse serum, the indicated “competitor” MAb was added.
Different concentrations of MAbs were used keeping in mind
their Kd values and the minimal amount of antibody needed to
obtain a reliable signal in the assay (Sanchez et al., 2005). The
following MAbs were added at a non-saturating concentration:
4E1 0.4 ng/100 μl (Kd 0.06 nM), 8B10 6 ng/100 μl (Kd
0.09 nM) and 11C2 18 ng/100 μl (Kd 0.24 nM) without washing
and the plate was incubated for 20 min at RT, which was
determined to be the optimal incubation time for MAb binding.
The purity of all MAbs was similar (about 60% pure) (data not
shown). Plates were then washed, and a 1:5000 dilution of ECL
anti-mouse IgG from sheep conjugated to horseradish peroxi-
dase (HRP) (Amersham Biosciences) was added and incubated
for 1 h at RT. Following a final wash, the wells were developed
as described above.For competition ELISAs using SVPs, a 1:32 dilution of
SVPs (unpelleted and in media with no serum) was coated on
plates with coating buffer overnight. Plates were blocked, and
horse serum dilutions added, from 1:80 to 1:4920 and incubated
for 1 h at RT. After incubation with horse serum, the indicated
“competitor” MAb was added. Different concentrations of
MAbs were used keeping in mind their Kd values (concentra-
tions at least 30-fold greater than their Kd values were used) and
the minimal amount of antibody needed to obtain a reliable
signal in the assay. The following competitor antibodies were
used at the following concentrations: 4E1 at 40 ng/100 μl (Kd
0.06 nM), 8B10 80 ng/100 μl (Kd 0.09 nM), 11C2 180 ng/
100 μl (Kd 0.24 nM), 17D7 375 ng/100 μl (Kd 0.83 nM)
(Sanchez et al., 2005). MAbs were added without washing and
the plate was incubated for 20 min at RT. A higher concentration
of MAbs was needed to obtain a reliable signal (OD) when
using SVPs than when using purified DIII. Subsequently, plates
were washed and developed as described above.
Production of WNV reporter virus particles (RVPs)
WNV RVPs were produced by transfection of 293T cells
with a combination of three different plasmids (Pierson et al.,
2006) using Lipofectamine 2000 according to the manufac-
turer's instructions. Preparation of RVPs using this system
was accomplished by transfection of pre-plated 293T cells in
a 10-cm dish with plasmids encoding 13 μg capsid-prM, 4 μg E
(wild-type or mutant) and 13 μg of WNV replicon expressing a
reporter gene (Renilla luciferase or GFP). Lipid–DNA com-
plexes were washed off transfected cells 12–16 h post infection
and replaced with a low glucose formulation of DMEM/10%
FCS/1% P/S/25 mM HEPES pH 8.0. RVP-containing super-
natants were harvested 48 h post-transfection, filtered through a
0.45 μm filter and frozen at −80 °C.
Reporter virus particle neutralization assay
For experiments with Renilla luciferase expressing particles,
8000 Vero cells were plated in 100 μl per well of a 96-well
white opaque tissue culture treated plate (Microtest™ Flat
Bottom, Falcon, Becton Dickinson Labware) and allowed to
sit for 1–6 h before infection. Infections were harvested at
42–46 h later, and cells analyzed using a commercially
available Renilla luciferase assay system (Promega) per
manufacturer instructions. Briefly, after removing the super-
natant, cells were lysed for 15 min at room temperature in
45 μl lysis buffer, and 45 μl of assay buffer with luciferase
substrate was added immediately before reading the reaction
in a Luminoskan Ascent luminometer (Thermo Electron
Corporation). For experiments with GFP expressing particles,
32,000 Vero cells in 100 μl per well were plated in a clear
96-well plate and allowed to adhere. Cells were harvested
36–40 h after infection, and GFP expression analyzed using a
Guava EasyCyte cytometer (Guava Technologies).
For experiments involving neutralization of RVPs with
monoclonal antibodies (MAbs), luciferase expressing particles
were used. MAbs were incubated with a 1:1000 dilution of WT
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for 1 h before infecting Vero cells as above. Four different
MAbs were used: 17D7 (a DI non-neutralizing antibody),
11C2 and 8B10 (DIII neutralizing antibodies) and E1 (DIII
neutralizing antibody) (Oliphant et al., 2005; Sanchez et al.,
2005). Two different concentrations of MAbs were used,
10 μg/ml or 0.1 μg/ml. Experiments were performed in triplicate.
For experiments involving neutralization of RVPs with horse
serum samples, serial dilutions of the indicated horse serum
were incubated with the indicated dilution of RVP (either
luciferase or GFP). For experiments using GFP expressing
particles, WTandΔ67IA RVPs were used at a dilution of 1:100.
For experiments using luciferase expressing particles, WT
particles were used at 1:1000 and Δ67IA RVPs were used at a
dilution of 1:400. For all concentrations of RVP used, WT and
mutant stocks, we empirically determined that antibody was in
excess by performing curves with different concentrations of
RVPs as detailed in Pierson et al. (2006). Horse serum dilutions
were filtered through a 0.2 μm-pore size filter before incubation
with RVPs. The initial dilution for the horse serum samples in
neutralization assays with WT or mutant RVPs ranged from
1:50 to 1:200 depending on the potency of the neutralizing
activity of the serum. Ten three-fold serial dilutions of horse
serum were performed in MEM. Neutralization curves for both
luciferase and GFP assays were evaluated using non-linear
regression analysis (GraphPad Prism 4, GraphPad Software,
Inc.). The concentration of horse serum required to neutralize
50% of infection (EC50 titers) was determined for all curves
with an R2 value of more than 0.7.
For experiments comparing neutralization of WT versus
mutant RVPs, the ratio of the EC50 values (WT/mutant) was
determined for each independent experiment in order to account
for the variability between assays and analyze the data in a pair
wise fashion. Statistical analysis was performed on the
calculated ratios using a two-tail paired t-test analysis
(GraphPad Prism 4, GraphPad Software, Inc.), with significance
determined as P<0.05.
DIII adsorption experiments
Purified WNV DIII protein (described above) was used to
remove DIII-specific antibodies from horse serum. 50 μl of
Talon Metal Affinity Resin (Clontech) was washed with PBS
and resuspended in 100 μl of PBS (No DIII samples) or PBS
with 40 μg of purified DIII protein. After overnight incubation
with or without DIII at 4 °C, beads were washed with PBS and
pelleted to remove unbound DIII protein. Subsequently, a 1:100
dilution of control, uninfected horse serum was added to the
beads as a blocking agent and incubated for 30 min at RT. WNV
positive or control serum was then added to the tubes to a final
dilution of 1:500. Therefore, each horse serum sample was
added to one tube with beads without DIII, and one tube with
beads with DIII. After 1 h incubation, beads were pelleted and
serum removed and filtered through a 0.2 μm filter.
Successful adsorption of DIII antibodies was determined by
ELISA as follows. 96-well plates were coated with 0.5 μg/ml of
DIII in coating buffer and incubated overnight. Plates wereblocked with PBS/0.05% Tween/10% FCS for 1 h. Subse-
quently, horse serum before incubation with beads (pre-beads
sample) or after incubation with beads (with and without DIII)
was added to the plate and incubated for 2 h at RT. Anti-horse
IgG–HRP conjugate was added, and plates developed as
described above. Neutralization assays were performed with
wild-type and Δ67IA RVP GFP stocks as described above
except the initial dilution for the horse serum samples used in
these experiments was 1:2000. Five five-fold serial dilutions of
horse serum were performed in MEM in order to obtain
sigmoidal curves for non-linear regression analysis as described
above for RVP GFP experiments.
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